(4) a clinical diagnosis of coronary disease as documented by a cardiologist. Patients with acute myocardial infarction, acute coronary syndrome, hypertrophic cardiomyopathy, congenital heart disease, primary pulmonary hypertension, lung disease, arrhythmogenic right ventricular cardiomyopathy, coronary artery bypass grafting, renal dysfunction (serum creatinine level >2.0 mg/dl) or moderate to severe CHF (New York Heart Association class III or IV) were excluded from the study.
Patients were stratified to subgroups based on angiographic findings as follows: patients without a coronary diameter stenosis >75% (no significant stenosis), patients with 1 vessel stenosis >75% (1-vessel disease), and patients with 2 or 3 vessel stenosis >75% (more than 2-vessel disease).
Informed consent was obtained from each patient before participation in the study, which was conducted according to a protocol approved by the Committee on Human Investigation at our institution.
Study Protocol
All patients were premedicated with an oral dose of diazepam (5 mg) and a right-sided cardiac catheterization was performed with a 7F Swan -Ganz catheter, and hemodynamic measurements were obtained while the patient rested on a bed in a supine position. Left-sided cardiac catheterization was performed and blood pressure was measured. The heart rate was monitored by electrocardiography. Blood samples for measuring BNP and NT-proBNP were collected simultaneously from the aortic root (AO) and coronary sinus (CS). A 6 Fr catheter for blood sampling was positioned in the CS, and the position of the catheter was confirmed as previously reported. 23 Blood sampling for measuring creatinine was also collected from the AO. Renal function was represented by the estimated glomerular filtration rate (eGFR) according to the MDRD equation. 24 In 36 patients after coronary revascularization without restenosis (restenosis was defined as ≥50% stenosis at follow up), blood samples for measuring BNP and NT-proBNP were collected 3 months later at follow-up angiography.
Measurement of BNP and NT-ProBNP
Plasma BNP concentrations were measured by a specific immunoradiometric assay for human BNP using a commercial kit (Shionogi, Japan) as previously reported. 4 Plasma levels of NT-proBNP concentrations were measured by using Elecsys proBNP sandwich immunoassay (Roche Diagnostics, Mannheim, Germany). The analytical range extends from 20 to 35,000 pg/ml. The normal range of NT-proBNP measured by this assay system is less than 55 pg/ml in the Japanese population as previously reported. 25 
Coronary Angiography
All patients underwent a coronary angiography using a commonly performed technique. The coronary angiograms were assessed by 2 experienced angiographers who used a validated quantitative coronary angiographic system (QCA-CMS 5.1, MEDIS, Leiden, Netherlands); these 2 angiographers were unaware of the plasma levels of BNP and NT-proBNP. We estimated the degree of CAD using the Gensini score, 26 which is a measure of the extent and severity of CAD and is computed by assigning a severity score to each coronary segment according to the degree of luminal narrowing and its geographic importance. Reduction in the diameter of the lumen and the roentgenographic appearance of concentric lesions, as well as eccentric plaques, were evaluated (reductions of 25, 50, 75, 90 and 99%, and complete occlusion values were given Gensini scores of 1, 
MI, myocardial infarction; PCI, percutaneous coronary intervention; LVEF, left ventricular ejection fraction; LVEDP, left ventricular end-diastolic pressure; eGFR, estimated glomerular filtration rate (using MDRD equation); NT-proBNP, N-terminal pro brain natriuretic peptide; CS, coronary sinus; AO, aortic root; BNP, brain natriuretic peptide; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II type 1 receptor blocker.
2, 4, 8, 16, and 32, respectively). For each principal vascular segment, a multiplier was assigned based on the functional significance of the myocardial area supplied by the segment: left main coronary artery, ×5; proximal segment of the left anterior descending coronary artery (LAD), ×2.5; proximal segment of the circumflex artery, ×2.5; mid-segment of the LAD, ×1.5; right coronary artery, distal segment of the LAD, posterolateral artery, and obtuse marginal artery, ×1; and others, ×0.5. 27
Statistical Analysis
All results are expressed as mean ± SE. A chi-square test or 1-way analysis of variance was used to determine differences between the groups. Univariate analyses were performed by using a Student's t-test. Because BNP, NTproBNP levels and the Gensini score were not normally distributed, the significance of the differences in mean levels between the groups was analyzed by the KruskalWallis rank test for unpaired values and by the Wilcoxon rank-sum test for paired values, and the log BNP, log NTproBNP and log Gensini score were used in correlations and regression models.
To evaluate the contribution to the secretion of NTproBNP and BNP, univariate and stepwise multivariate analyses were used to compare 10 variables including hemodynamic parameters and the Gensini score, which is a measure of the extent of myocardial ischemia. Multivariate logistic regression analysis was performed to determine independent associations between the presence of significant coronary artery stenosis and the following variables: age (as a continuous variable), gender, NT-proBNP in the AO at a cut-off level of 360 pg/ml, BNP in the AO at a cut-off level of 110 pg/ml, diabetes mellitus, hyperlipidemia, eGFR (as a continuous variable) and left ventricular ejection fraction (LVEF) <50%. A p value <0.05 was regarded as significant.
Results

Patient Characteristics
The detailed baseline characteristics of the study population are given in Table 1 . No significant differences in age, male gender, risk factors or hemodynamic parameters were observed between the subgroups with and without coronary artery stenosis. Previous percutaneous coronary intervention (PCI) was more prevalent in patients without coronary artery stenosis. Laboratory findings of eGFR and (CS-AO) BNP were not different between the subgroups. However, NT-proBNP in the AO and (CS-AO) NT-proBNP significantly increased with the severity of coronary artery stenosis (Table 1) .
Relationship Between the Transcardiac Increase of BNP and NT-ProBNP and the Severity of Significant Coronary Artery Stenosis
Both the level of BNP and NT-proBNP in the CS were significantly higher than those in the AO (Fig 1) . There was a strong correlation between the transcardiac increase of NT-proBNP and that in the AO, as well as a similar correlation for BNP (Figs 2A,B) . The transcardiac increase in NTproBNP levels according to the number of involved vessels with more than 75% diameter stenosis is shown in Fig 3A. In patients without critical stenosis, it was 140±20 pg/ml, for those with 1-vessel disease, it was 175±24 pg/ml and for those with more than 2-vessel disease, it was 315±73 pg/ml. The transcardiac increase in the plasma level of NT-proBNP increased significantly with the severity of coronary artery stenosis, but the plasma level of BNP did not (Fig 3B) . 
Relationship Between the Molar Ratio of the (CS-AO) NT-Pro-BNP/(CS-AO) BNP and the Severity of Coronary Artery Stenosis
The molar ratio of the (CS-AO) NT-proBNP/(CS-AO) BNP in the present study population was less than 1. The transcardiac increase of NT-proBNP (pmol/L) was significantly lower than that of BNP (pmol/L) (22.3±2.3 vs 45.2±3.3, p<0.0001). The molar ratio of the (CS-AO) NTproBNP/(CS-AO) BNP increased with the severity of coronary artery stenosis (p=0.019) (Fig 4) .
Change in the Molar Ratio of the (CS-AO) NT-ProBNP/ (CS-AO) BNP Before and After PCI
In 36 patients after coronary revascularization who did not have restenosis (restenosis was defined as ≥50% stenosis at follow up), we were able to measure the transcardiac increase of NT-proBNP and BNP 3 months later. The molar ratio of the transcardiac increase of NT-proBNP to the transcardiac increase of BNP significantly decreased after coronary revascularization (p=0.018; Fig 5) . 
Univariate and Multivariate Regulators of the Transcardiac Increase of NT-ProBNP in Patients With CAD
Univariate and stepwise multivariate analyses of the association between the transcardiac gradients of plasma NT-proBNP and multiple variables including hemodynamic parameters and the Gensini score are shown in Table 2 . The transcardiac increase of NT-proBNP was positively correlated with the Gensini score on univariate analysis (Fig 6A) . Among these variables, LVEF (p<0.0001), left ventricular end-diastolic pressure (LVEDP) (p=0.004) and the log Gensini score (p=0.008) were significantly independent regulators of the transcardiac increase of plasma NTproBNP in patients with CAD.
Univariate and Multivariate Regulators of the Transcardiac Increase of BNP in Patients With CAD
The transcardiac increase of BNP was positively correlated with the Gensini score in univariate analysis (Fig 6B) . Among these variables, LVEF (p<0.0001) and LVEDP (p=0.0005) were significant independent regulators of the transcardiac increase of plasma BNP in patients with CAD. However, the log Gensini score was not an independent regulator of the transcardiac increase of plasma BNP (Table 3) .
Plasma Level of NT-ProBNP in the AO as a Predictor of Significant CAD
The plasma level of BNP and NT-proBNP in the AO were increased with the severity of coronary artery stenosis (Table 1) . To predict significant coronary disease (at least 1 vessel disease), the area under the receiver operating characteristic curve was 0.58 (95% confidence interval (CI) 0.51-0.66) for NT-proBNP and 0.57 (95% CI 0.50-0.64) for BNP. An optimized cut-off level of NT-proBNP was 360 pg/ml (odds ratio 2.41, 95% CI 1.38-4.31) and for BNP it was 110 pg/ml (odds ratio 1.96, 95% CI 1.10-3.62).
Discussion
We evaluated the transcardiac increase of BNP and NTproBNP as a marker of cardiac secretion in a head-to-head comparison between 2 clinically approved assays (BNP: Shionogi and NT-proBNP: Roche) in patients with stable CAD. In the present study, the transcardiac increase of plasma NT-proBNP was significantly increased with the severity of coronary artery stenosis, but this was not significant in the case of the BNP plasma level. In addition, the molar ratio of the transcardiac increase of NT-proBNP to the transcardiac increase of BNP increased with the severity of coronary artery stenosis and decreased after coronary revascularization. Moreover, the Gensini score, which is a measure of the extent and severity of CAD, is a significant predictor of the transcardiac increase of NT-proBNP independent of LVEF and LVEDP, which are the major regulators of secretion of BNP systems. The mechanism underlying these findings remains unexplained; the present study findings might be consistent with the previous experimental study conducted by Goetze et al. 18 They reported that myo- cardial hypoxia stimulates cardiac BNP expression and releases predominantly proBNP from ventricular myocytes and significantly increases plasma proBNP. Taken together with the present findings, the measurements of plasma NTproBNP might be useful to estimate chronic myocardial hypoxia caused by coronary artery stenosis. In the present study, the molar ratio of the transcardiac increase of NT-proBNP to the transcardiac increase of BNP increased with the severity of coronary artery stenosis (Fig 4) . Although further studies are needed to clarify the molecular forms of BNPs using radioimmunoassay combined with gel chromatography or high performance liquid chromatography, the secretion pattern of the BNP to NTproBNP molar ratio might change because of the extent of coronary artery stenosis. Actually, the molar ratio of the transcardiac increase of NT-proBNP to the transcardiac increase of BNP significantly decreased after coronary revascularization (Fig 5) .
It is currently thought that the main stimulus for natriuretic peptide release is increased left ventricular (LV) wall stress. 19, 28, 29 Myocardial ischemia might induce a potentially reversible increase in regional wall stress that might lead to the augmented expression and release of natriuretic peptides. However, other mechanisms related to ischemia, independent of LV wall stress, might lead to increased expression and release of natriuretic peptides. 18, 30 Recent studies suggest that the augmented release of BNP after brief periods of ischemia can occur without concomitant change in LVEDP, suggesting that ischemia, per se, might be the stimulus for BNPs release. 16 An association among BNP or NT-proBNP levels, the number of diseased vessels, and the location of stenoses has been reported previously. 11, 12, 31 In the present study, the Gensini score, which is a more meaningful measurement of the severity of CAD, is a significant predictor of the secretion of NT-proBNP (but not so for BNP), and is independent of hemodynamic overload such as LVEF and LVEDP (Table 3) . Therefore, the present study, by direct sampling from the CS and the AO, supports observations and suggests that plasma NT-proBNP might be superior to BNP in terms of assessing the severity of CAD. The present study could not estimate the mechanism of the superiority of NTproBNP to BNP (Fig 3) , but the finding that proBNP levels are relatively higher than BNP in culture medium from hypoxic ventricular cells 18 might support our clinical data. In clinical practice, our findings might support the usefulness of incremented NT-proBNP levels in diagnosing and managing myocardial ischemia in patients with stable CAD. 10, 32 
Limitations
Several limitations should be considered in interpreting our results. First, there were more patients in the group without significant stenosis who had previously undergone coronary intervention than there were in the other groups. Second, diastolic function was not investigated in this study. Third, the number of patients with more than 2-vessel disease was relatively low. Finally, not all the patients could undergo thallium radionuclide imaging and exercise testing as the gold standard for the definition of myocardial ischemia.
Conclusions
The transcardiac increase of NT-proBNP as a marker of NT-proBNP secretion increases with the severity of coronary artery stenosis, independent of hemodynamic overload, and plasma NT-proBNP might be superior to BNP to assess the severity of patients with stable CAD. The association we observed between the transcardiac increase of NT-proBNP and the extent of coronary artery stenosis suggests a potential explanation for the increased risk of future coronary events associated with elevations in NT-proBNP in patients with stable CAD.
